Exelixis receives $20 million for new anticancer molecule
This article was originally published in Scrip
Executive Summary
Exelixis will receive $20 million in milestones after Bristol-Myers Squibb exercised its option to develop and commercialise Exelixis's XL413, a potential first-in-class anticancer therapy. The late-stage preclinical selective inhibitor of Cdc7, which is thought to play an important role in cancer cells, is thought to be the most clinically advanced inhibitor of its kind. Exelixis will co-develop and co-commercialise XL413 in the US and the two firms will halve profits equally. BMS will be responsible for all non-US activities and Exelixis will receive double-digit royalties on product sales outside the US. XL413 is the second molecule that BMS is taking forward as part of a collaboration the two firms agreed in January 2007 whereby Exelixis identifies preclinical drug candidates against selected targets. This January BMS chose to develop Exelixis's anticancer XL139, an inhibitor of the hedgehog signalling pathway, for which Exelixis also received $20 million.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.